Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 180.57
UTHR's Cash to Debt is ranked higher than
51% of the 940 Companies
in the Global Biotechnology industry.

( Industry Median: 101.30 vs. UTHR: 180.57 )
Ranked among companies with meaningful Cash to Debt only.
UTHR' s Cash to Debt Range Over the Past 10 Years
Min: 0.69  Med: 20.40 Max: 15951.56
Current: 180.57
0.69
15951.56
Equity to Asset 0.78
UTHR's Equity to Asset is ranked higher than
59% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.70 vs. UTHR: 0.78 )
Ranked among companies with meaningful Equity to Asset only.
UTHR' s Equity to Asset Range Over the Past 10 Years
Min: 0.37  Med: 0.68 Max: 0.97
Current: 0.78
0.37
0.97
Interest Coverage 328.92
UTHR's Interest Coverage is ranked lower than
58% of the 375 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. UTHR: 328.92 )
Ranked among companies with meaningful Interest Coverage only.
UTHR' s Interest Coverage Range Over the Past 10 Years
Min: 2.02  Med: 16.20 Max: 147.63
Current: 328.92
2.02
147.63
F-Score: 7
Z-Score: 10.94
M-Score: -1.77
WACC vs ROIC
15.29%
109.01%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 71.49
UTHR's Operating margin (%) is ranked higher than
98% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -72.99 vs. UTHR: 71.49 )
Ranked among companies with meaningful Operating margin (%) only.
UTHR' s Operating margin (%) Range Over the Past 10 Years
Min: -29.15  Med: 26.68 Max: 47.69
Current: 71.49
-29.15
47.69
Net-margin (%) 59.96
UTHR's Net-margin (%) is ranked higher than
97% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -74.36 vs. UTHR: 59.96 )
Ranked among companies with meaningful Net-margin (%) only.
UTHR' s Net-margin (%) Range Over the Past 10 Years
Min: -15.2  Med: 21.97 Max: 46.33
Current: 59.96
-15.2
46.33
ROE (%) 65.50
UTHR's ROE (%) is ranked higher than
99% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -31.54 vs. UTHR: 65.50 )
Ranked among companies with meaningful ROE (%) only.
UTHR' s ROE (%) Range Over the Past 10 Years
Min: -10.05  Med: 19.34 Max: 46.04
Current: 65.5
-10.05
46.04
ROA (%) 44.45
UTHR's ROA (%) is ranked higher than
98% of the 944 Companies
in the Global Biotechnology industry.

( Industry Median: -26.66 vs. UTHR: 44.45 )
Ranked among companies with meaningful ROA (%) only.
UTHR' s ROA (%) Range Over the Past 10 Years
Min: -5.86  Med: 12.09 Max: 32.03
Current: 44.45
-5.86
32.03
ROC (Joel Greenblatt) (%) 296.07
UTHR's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -357.95 vs. UTHR: 296.07 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
UTHR' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -43.1  Med: 67.40 Max: 215.39
Current: 296.07
-43.1
215.39
Revenue Growth (3Y)(%) 18.50
UTHR's Revenue Growth (3Y)(%) is ranked higher than
75% of the 491 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. UTHR: 18.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
UTHR' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 18.5  Med: 37.90 Max: 264.9
Current: 18.5
18.5
264.9
EBITDA Growth (3Y)(%) 32.40
UTHR's EBITDA Growth (3Y)(%) is ranked higher than
84% of the 493 Companies
in the Global Biotechnology industry.

( Industry Median: -0.70 vs. UTHR: 32.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
UTHR' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -56.2  Med: 13.80 Max: 128
Current: 32.4
-56.2
128
EPS Growth (3Y)(%) 30.60
UTHR's EPS Growth (3Y)(%) is ranked higher than
84% of the 499 Companies
in the Global Biotechnology industry.

( Industry Median: -5.10 vs. UTHR: 30.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
UTHR' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -50.7  Med: 14.90 Max: 154.4
Current: 30.6
-50.7
154.4
» UTHR's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-28)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

UTHR Guru Trades in Q2 2015

Paul Tudor Jones 7,375 sh (+309.72%)
Jim Simons 811,578 sh (+81.76%)
First Eagle Investment 426,880 sh (+14.57%)
John Hussman 25,000 sh (unchged)
Ken Fisher 2,450 sh (unchged)
Louis Moore Bacon Sold Out
Joel Greenblatt 261,125 sh (-10.29%)
Lee Ainslie 3,770 sh (-16.22%)
» More
Q3 2015

UTHR Guru Trades in Q3 2015

Lee Ainslie 9,640 sh (+155.70%)
First Eagle Investment 548,807 sh (+28.56%)
Ken Fisher 2,918 sh (+19.10%)
Joel Greenblatt 301,205 sh (+15.35%)
Jim Simons 866,778 sh (+6.80%)
John Hussman 25,000 sh (unchged)
Paul Tudor Jones Sold Out
» More
Q4 2015

UTHR Guru Trades in Q4 2015

Paul Tudor Jones 2,900 sh (New)
George Soros 4,400 sh (New)
Ray Dalio 28,161 sh (New)
Lee Ainslie 10,570 sh (+9.65%)
Joel Greenblatt 328,310 sh (+9.00%)
Ken Fisher 3,137 sh (+7.51%)
John Hussman Sold Out
First Eagle Investment Sold Out
Jim Simons 552,078 sh (-36.31%)
» More
Q1 2016

UTHR Guru Trades in Q1 2016

David Dreman 125 sh (New)
Ray Dalio 85,833 sh (+204.79%)
Lee Ainslie 20,930 sh (+98.01%)
Paul Tudor Jones 4,600 sh (+58.62%)
Joel Greenblatt 362,565 sh (+10.43%)
George Soros Sold Out
Ken Fisher 3,092 sh (-1.43%)
Jim Simons 474,578 sh (-14.04%)
» More
» Details

Insider Trades

Latest Guru Trades with UTHR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:XSWX:RO, OCSE:NOVO B, NAS:AMGN, NAS:GILD, NAS:CELG, NAS:BIIB » details
Traded in other countries:UTH.Germany,
United Therapeutics Corp is a biotechnology company. The Company is engaged in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.

United Therapeutics Corp was incorporated in Delaware in June 1996. It is a biotechnology company. The Company is engaged in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions. Its key therapeutic products and product candidates include: Prostacyclin Analogues, Prostacyclin analogues are stable synthetic forms of prostacyclin, an important molecule produced by the body that has powerful effects on blood vessel health and function. Its product is Remodulin (treprostinil) Injection (Remodulin), which is administered subcutaneously (under the skin) or intravenously (in the vein) for the treatment of pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise. Phosphodiesterase Type 5 (PDE-5) Inhibitor. PDE-5 inhibitors act to inhibit the degradation of cyclic guanosine monophosphate (cyclic GMP) in cells. Cyclic GMP is activated by nitric oxide (NO), a naturally occurring substance in the body that mediates the relaxation of vascular smooth muscle. Monoclonal Antibody (MAb), MAbs act by targeting tumor-associated antigens located on the surfaces of cancer cells to activate a patient's immune system against the cancer cells. The Company is developing the antibody Ch14.18 MAb for the treatment of neuroblastoma, under an agreement with the National Cancer Institute (NCI) of the United States National Institutes of Health (NIH). Glycobiology Antiviral Agents, Glycobiology antiviral agents are a novel class of small, sugar-like molecules that have shown preclinical indications of efficacy against a broad range of viruses. Cell-Based Therapy,iIn 2011, the Company entered into a license agreement with Pluristem Ltd. (Pluristem) to develop and commercialize its cell-based product known as PLacental eXpanded (PLX) cells for the treatment of PAH. Lung Transplantation, the Company is engaged in developing engineered lungs and lung tissue for transplant into patients suffering from PAH and other lung diseases. The Company competes with a number of approved products including the following: Flolan, Ventavis, Ilomedin , Tracleer, Revatio, Letairis , Veletri, Adempas, Opsumit , generic epoprostenol and generic sildenafil citrate. The Company's operations must comply with extensive laws and regulations in the United States and other countries, including FDA regulations.

Ratios

vs
industry
vs
history
P/E(ttm) 6.46
UTHR's P/E(ttm) is ranked higher than
91% of the 254 Companies
in the Global Biotechnology industry.

( Industry Median: 29.15 vs. UTHR: 6.46 )
Ranked among companies with meaningful P/E(ttm) only.
UTHR' s P/E(ttm) Range Over the Past 10 Years
Min: 5.81  Med: 25.06 Max: 172.33
Current: 6.46
5.81
172.33
Forward P/E 7.94
UTHR's Forward P/E is ranked higher than
83% of the 94 Companies
in the Global Biotechnology industry.

( Industry Median: 17.15 vs. UTHR: 7.94 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 6.46
UTHR's PE(NRI) is ranked higher than
90% of the 244 Companies
in the Global Biotechnology industry.

( Industry Median: 30.43 vs. UTHR: 6.46 )
Ranked among companies with meaningful PE(NRI) only.
UTHR' s PE(NRI) Range Over the Past 10 Years
Min: 5.82  Med: 24.44 Max: 171.34
Current: 6.46
5.82
171.34
Price/Owner Earnings (ttm) 7.84
UTHR's Price/Owner Earnings (ttm) is ranked higher than
87% of the 146 Companies
in the Global Biotechnology industry.

( Industry Median: 37.01 vs. UTHR: 7.84 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
UTHR' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 7.02  Med: 25.90 Max: 570.89
Current: 7.84
7.02
570.89
P/B 3.12
UTHR's P/B is ranked higher than
55% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: 3.36 vs. UTHR: 3.12 )
Ranked among companies with meaningful P/B only.
UTHR' s P/B Range Over the Past 10 Years
Min: 2.01  Med: 4.16 Max: 10.39
Current: 3.12
2.01
10.39
P/S 3.88
UTHR's P/S is ranked higher than
78% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 12.41 vs. UTHR: 3.88 )
Ranked among companies with meaningful P/S only.
UTHR' s P/S Range Over the Past 10 Years
Min: 2.88  Med: 6.32 Max: 17.8
Current: 3.88
2.88
17.8
PFCF 16.92
UTHR's PFCF is ranked higher than
73% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 26.95 vs. UTHR: 16.92 )
Ranked among companies with meaningful PFCF only.
UTHR' s PFCF Range Over the Past 10 Years
Min: 9.78  Med: 21.04 Max: 618.25
Current: 16.92
9.78
618.25
POCF 14.62
UTHR's POCF is ranked higher than
69% of the 203 Companies
in the Global Biotechnology industry.

( Industry Median: 24.65 vs. UTHR: 14.62 )
Ranked among companies with meaningful POCF only.
UTHR' s POCF Range Over the Past 10 Years
Min: 8.33  Med: 18.84 Max: 50.87
Current: 14.62
8.33
50.87
EV-to-EBIT 2.97
UTHR's EV-to-EBIT is ranked higher than
83% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 24.27 vs. UTHR: 2.97 )
Ranked among companies with meaningful EV-to-EBIT only.
UTHR' s EV-to-EBIT Range Over the Past 10 Years
Min: -31.2  Med: 18.60 Max: 120.9
Current: 2.97
-31.2
120.9
EV-to-EBITDA 2.93
UTHR's EV-to-EBITDA is ranked higher than
84% of the 304 Companies
in the Global Biotechnology industry.

( Industry Median: 21.30 vs. UTHR: 2.93 )
Ranked among companies with meaningful EV-to-EBITDA only.
UTHR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -33.7  Med: 16.80 Max: 102.2
Current: 2.93
-33.7
102.2
PEG 0.17
UTHR's PEG is ranked higher than
97% of the 93 Companies
in the Global Biotechnology industry.

( Industry Median: 2.28 vs. UTHR: 0.17 )
Ranked among companies with meaningful PEG only.
UTHR' s PEG Range Over the Past 10 Years
Min: 0.2  Med: 0.47 Max: 2.42
Current: 0.17
0.2
2.42
Shiller P/E 28.84
UTHR's Shiller P/E is ranked higher than
75% of the 53 Companies
in the Global Biotechnology industry.

( Industry Median: 51.13 vs. UTHR: 28.84 )
Ranked among companies with meaningful Shiller P/E only.
UTHR' s Shiller P/E Range Over the Past 10 Years
Min: 25.91  Med: 50.69 Max: 543.3
Current: 28.84
25.91
543.3
Current Ratio 3.64
UTHR's Current Ratio is ranked lower than
58% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.55 vs. UTHR: 3.64 )
Ranked among companies with meaningful Current Ratio only.
UTHR' s Current Ratio Range Over the Past 10 Years
Min: 0.96  Med: 6.04 Max: 64.22
Current: 3.64
0.96
64.22
Quick Ratio 3.39
UTHR's Quick Ratio is ranked lower than
57% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.27 vs. UTHR: 3.39 )
Ranked among companies with meaningful Quick Ratio only.
UTHR' s Quick Ratio Range Over the Past 10 Years
Min: 0.9  Med: 5.60 Max: 64.22
Current: 3.39
0.9
64.22
Days Inventory 595.67
UTHR's Days Inventory is ranked lower than
98% of the 446 Companies
in the Global Biotechnology industry.

( Industry Median: 127.50 vs. UTHR: 595.67 )
Ranked among companies with meaningful Days Inventory only.
UTHR' s Days Inventory Range Over the Past 10 Years
Min: 118.32  Med: 166.79 Max: 391.94
Current: 595.67
118.32
391.94
Days Sales Outstanding 47.17
UTHR's Days Sales Outstanding is ranked higher than
64% of the 606 Companies
in the Global Biotechnology industry.

( Industry Median: 63.27 vs. UTHR: 47.17 )
Ranked among companies with meaningful Days Sales Outstanding only.
UTHR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 36.71  Med: 45.26 Max: 51.34
Current: 47.17
36.71
51.34
Days Payable 55.93
UTHR's Days Payable is ranked lower than
52% of the 435 Companies
in the Global Biotechnology industry.

( Industry Median: 58.35 vs. UTHR: 55.93 )
Ranked among companies with meaningful Days Payable only.
UTHR' s Days Payable Range Over the Past 10 Years
Min: 18.67  Med: 52.98 Max: 246.85
Current: 55.93
18.67
246.85

Valuation & Return

vs
industry
vs
history
Price/Net Cash 10.63
UTHR's Price/Net Cash is ranked lower than
72% of the 670 Companies
in the Global Biotechnology industry.

( Industry Median: 5.01 vs. UTHR: 10.63 )
Ranked among companies with meaningful Price/Net Cash only.
UTHR' s Price/Net Cash Range Over the Past 10 Years
Min: 1.51  Med: 10.55 Max: 160.03
Current: 10.63
1.51
160.03
Price/Net Current Asset Value 6.42
UTHR's Price/Net Current Asset Value is ranked lower than
59% of the 783 Companies
in the Global Biotechnology industry.

( Industry Median: 4.96 vs. UTHR: 6.42 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
UTHR' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.46  Med: 10.65 Max: 5533
Current: 6.42
1.46
5533
Price/Tangible Book 3.13
UTHR's Price/Tangible Book is ranked higher than
63% of the 949 Companies
in the Global Biotechnology industry.

( Industry Median: 3.90 vs. UTHR: 3.13 )
Ranked among companies with meaningful Price/Tangible Book only.
UTHR' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.16  Med: 4.01 Max: 18.16
Current: 3.13
1.16
18.16
Price/Projected FCF 1.00
UTHR's Price/Projected FCF is ranked higher than
91% of the 180 Companies
in the Global Biotechnology industry.

( Industry Median: 3.90 vs. UTHR: 1.00 )
Ranked among companies with meaningful Price/Projected FCF only.
UTHR' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.95  Med: 3.89 Max: 232.67
Current: 1
0.95
232.67
Price/Median PS Value 0.62
UTHR's Price/Median PS Value is ranked higher than
74% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. UTHR: 0.62 )
Ranked among companies with meaningful Price/Median PS Value only.
UTHR' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.5  Med: 1.34 Max: 288.8
Current: 0.62
0.5
288.8
Price/Peter Lynch Fair Value 0.26
UTHR's Price/Peter Lynch Fair Value is ranked higher than
97% of the 60 Companies
in the Global Biotechnology industry.

( Industry Median: 1.68 vs. UTHR: 0.26 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
UTHR' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.25  Med: 1.16 Max: 5.82
Current: 0.26
0.25
5.82
Price/Graham Number 0.95
UTHR's Price/Graham Number is ranked higher than
88% of the 210 Companies
in the Global Biotechnology industry.

( Industry Median: 3.11 vs. UTHR: 0.95 )
Ranked among companies with meaningful Price/Graham Number only.
UTHR' s Price/Graham Number Range Over the Past 10 Years
Min: 0.9  Med: 2.50 Max: 6.18
Current: 0.95
0.9
6.18
Earnings Yield (Greenblatt) (%) 33.50
UTHR's Earnings Yield (Greenblatt) (%) is ranked higher than
95% of the 1090 Companies
in the Global Biotechnology industry.

( Industry Median: -9.50 vs. UTHR: 33.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
UTHR' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.8  Med: 4.80 Max: 34.58
Current: 33.5
0.8
34.58
Forward Rate of Return (Yacktman) (%) 34.79
UTHR's Forward Rate of Return (Yacktman) (%) is ranked higher than
83% of the 115 Companies
in the Global Biotechnology industry.

( Industry Median: 14.18 vs. UTHR: 34.79 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
UTHR' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -1.4  Med: 0.90 Max: 56.9
Current: 34.79
-1.4
56.9

More Statistics

Revenue (TTM) (Mil) $1,507
EPS (TTM) $ 18.09
Beta1.81
Short Percentage of Float23.37%
52-Week Range $102.50 - 190.13
Shares Outstanding (Mil)44.62

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 1,686 1,917 1,894
EPS ($) 13.25 14.84 16.32
EPS without NRI ($) 13.25 14.84 16.32
EPS Growth Rate
(3Y to 5Y Estimate)
0.98%
» More Articles for UTHR

Headlines

Articles On GuruFocus.com
United Therapeutics Is a Value Investor's Biotech Dream Apr 28 2016 
Cummins and Deckers are Candidates for a January Bounce Nov 20 2015 
Estimated Revenue Up 5% Stock Screen Nov 18 2015 
FDA Approval Of Cancer Drug Catapults United Therapeutics Shares By 2% Mar 11 2015 
Weekly CFO Sells Highlight: United Therapeutics Corp, Williams Companies Inc, Facebook Inc. Oct 12 2014 
Here are 5 Good Companies to Consider Investing In Right Now Feb 11 2014 
High-Dollar Insider Sells - Zuckerberg Sells 41M Facebook Shares Dec 27 2013 
John Hussman's Third Quarter Top 5 Nov 07 2013 
Vanguard Health Care Fund Selling Update Oct 30 2013 
Super-Fast Growing Mid-Cap Growth Stocks with Explosive Returns May 09 2013 

More From Other Websites
United Therapeutics Corp. breached its 50 day moving average in a Bullish Manner : UTHR-US : May 24,... May 24 2016
ETF’s with exposure to United Therapeutics Corp. : May 16, 2016 May 16 2016
Aging Is So Yesterday May 16 2016
SteadyMed Provides Corporate Update and Reports First Quarter 2016 Financial Results May 11 2016
United Therapeutics Corp. :UTHR-US: Earnings Analysis: Q1, 2016 By the Numbers May 10 2016
UNITED THERAPEUTICS CORP Financials May 03 2016
United (UTHR) Stock Declines Despite Q1 Earnings Beat Apr 29 2016
United Therapeutics downgraded by Ladenburg Thalmann Apr 29 2016
The 52-Week Low Club for Thursday Apr 28 2016
Edited Transcript of UTHR earnings conference call or presentation 28-Apr-16 1:00pm GMT Apr 28 2016
Roger Jeffs out in executive shakeup at drugmaker United Therapeutics Apr 28 2016
United Therapeutics Corp Earnings Call scheduled for 9:00 am ET today Apr 28 2016
Q1 2016 United Therapeutics Corp Earnings Release - Before Market Open Apr 28 2016
UNITED THERAPEUTICS CORP Files SEC form 8-K, Change in Directors or Principal Officers Apr 28 2016
United Therapeutics Corporation Announces Executive Leadership Changes Apr 28 2016
United Therapeutics Corporation Reports First Quarter 2016 Financial Results Apr 28 2016
United Therapeutics beats 1Q profit forecasts Apr 28 2016
United Therapeutics beats 1Q profit forecasts Apr 28 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)